My watch list
my.bionity.com  
Login  

ViGeneron is a next generation gene therapy company dedicated to develop the innovative medicines of the future. Our team seeks to solve the major limitations of current gene therapy approaches.

ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich.

More about ViGeneron
  • News

    Start-up ViGeneron announces research collaboration with Daiichi Sankyo

    ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmi ... more

    ViGeneron and Biogen collaborate

    ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered A ... more

    ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

    ViGeneron GmbH announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE